TRIM3 suppresses oncogenic C-MYC expression in GBM, resulting in a lower levels of stem cell markers CD133, Nestin, and Nanog, and subsequently reducing GBM neurosphere growth and confirming a pro-differentiation function for TRIM3 (Chen et al., 2014). The gene discussed is MYC; the disease is glioblastoma.